Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK2735 oral formulation for weight management in obesity and overweight
NCT06828055Phase 2Completed
- Sponsor
- Viking Therapeutics
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VK-2735 in obesity, sponsored by Viking Therapeutics. Started Dec 2024; status: completed.
02
Drugs
VK-2735
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06828055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828055.